GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology company developing Molecular and Artificial Intelligence tools to investigate DNA structural and dynamic changes, in particular in the human genome, is pleased to announce a partnership with GIPTIS, the future Euro Mediterranean Institute founded by Professor Nicolas Lévy, head of the Medical Genetic Department at the renowned hospital of “La Timone” in Marseille. The aim of this partnership is to accelerate and facilitate the diagnosis and treatment of patients, thanks to Genomic Vision proprietary technology and expertise.
In order to improve the management of patients affected by rare genetic diseases, GIPTIS has defined as main objectives to accelerate diagnosis, increase research capacity, multiply the number of effective treatments and improve the care of patients and families.
Professor Nicolas Lévy explains: “Genomic Vision has developed a powerful technology that helps to understand complex genetic abnormalities, in particular in aging and neurological diseases, two therapeutic areas with high unmet clinical needs. It is really helpful in particular to characterize genomic regions with highly repeated sequences for which NGS technologies are not efficient enough.”
Terms of the partnership include several research programs with the development of news assays targeting specific genetic disorders on which Genomic Vision will have exclusive commercialization rights.
Aaron Bensimon, CEO and co-founder of Genomic Vision, adds: “It is the fusion between technological innovation and unmet clinical needs that will cross the frontiers and will bring to the doctors and patients novel tests. Genomic Vision and GIPTIS are the appropriate partners to develop such a novel approach. GIPTIS will bring to GV an important source of unmet medical need in the field of neurological diseases and will be a major asset for the development and validation of these new tests. We are very proud to have been selected by this prestigious institute to participate in this outstanding project. It is not only an opportunity to set-up new IVD assays, but also an opening to Southern markets in which genetic disease rates are higher than elsewhere.”
Today, rare genetic diseases affect 3 million people in France, more than cancer and Alzheimer’s disease combined, and 50 million around the Mediterranean. More than 95% of patients are without adequate treatment and 60% of them are children.
In the majority of cases, these diseases are serious, disabling, chronic and have an impact on entire families.
The aim of GIPTIS: to treat patients better, faster and on a larger scale by facilitating collaborations between the best of the public and private sectors, academic and industrial worlds. GIPTIS unites medical teams, fundamental and applied research teams, start-ups, drug companies and patients associations in the same innovative place of excellence.
GIPTIS faces 4 challenges: accelerate the diagnoses, increase research capacity, multiply the number of effective treatments, improve care for patients and families.
Founded by internationally acclaimed geneticist, Professor Nicolas Lévy, GIPTIS will be a non-profit foundation with mixed governance, for successful cooperation between private and public sectors.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing molecular assays and Artificial Intelligence tools to control quality and safety of genetically modified genomes, in particular in genome editing technologies and biomanufacturing processes. These tools are currently use for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com.
Membre des indices CAC® Mid & Small et CAC® All-Tradable